quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:40:00·59d
PRRelease
Palisade Bio Inc. logo

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

PALI· Palisade Bio Inc.
Health Care
Original source

Companies

  • PALI
    Palisade Bio Inc.
    Health Care

Recent analyst ratings

  • Apr 9UpdateWolfe Research$7.00
  • Mar 26UpdateH.C. Wainwright$7.00
  • Feb 25UpdateStifel$5.00
  • Jan 9UpdateB. Riley Securities$7.00
  • Dec 29UpdatePiper Sandler$25.00
  • Feb 2UpdateLadenburg Thalmann$5.00

Related

  • SEC6d
    SEC Form PRE 14A filed by Palisade Bio Inc.
  • PR7d
    Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
  • ANALYST14d
    Wolfe Research initiated coverage on Palisade Bio with a new price target
  • PR15d
    Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
  • SEC21d
    Palisade Bio Inc. filed SEC Form 8-K: Other Events
  • PR24d
    Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease
  • ANALYST28d
    H.C. Wainwright initiated coverage on Palisade Bio with a new price target
  • SEC34d
    SEC Form 10-K filed by Palisade Bio Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022